Oncorus closed a $61M Series A in July 2016 led by MPM Capital. Also joining the round were Deerfield Management, Arkin Bio Ventures, Celgene, Inc, and Astellas.
At Oncorus, we are committed to bringing innovative therapies to patients in need.
Oncorus retains full worldwide rights to its platform and all products in our pipeline. We are currently exploring partnership opportunities. If you have an interest in our platform or products and believe we can work together to achieve this vision, please reach out at firstname.lastname@example.org.